Our Science

The multifaceted function of regulatory T cells (Tregs) makes them an attractive therapeutic modality

Multi-functional

Tregs perform multiple biologic functions to shut down immune response.

Tissue repair

Tregs contribute to tissue regenration.

Amplified effect

Tregs turn other cells in the inflamatory environment into Immune Regulatory cells – infectious tolerance.

Dual action

Act both at sites of inflamation and draining lymphoid tissues.

Tolerogenic Immune Regulation

Tregs suppress function of targeted cells and other cells in the environment – bystander suppression.

SBT-77-7101 utilizes Tregs natural functions and presents a potential for a curative one-and-done treatment

SBT-77-7101 is a genetically modified stable CAR-Treg to treat rheumatoid arthritis and other autoimmune and inflammatory diseases.

It is designed to target disease-specific antigens.

Truncated EGFR TAG – Cell surface-expressed TAG to allow for tracking and cell isolation.

Chimeric antigen receptor (CAR) is a specially engineered receptor added to immune cells to help them recognize and attack specific targets.

CARs combine parts of antigen-recognition structures with signaling domains to deliver a coordinated immune activation to enable selectively enhanced immune reactivity.

A targeting CAR is a specific antigen-recognition molecule on the surface of a cell that immune therapies are designed to recognize and trigger cell activation.

SBT-77-7101 is designed to target citrullinated proteins (Cit-P), which drive autoimmune and inflammatory responses and contribute to the development of several autoimmune diseases, including rheumatoid arthritis, hidradenitis suppurativa, and other inflammatory diseases such as chronic obstructive pulmonary disease and acute respiratory distress syndromes.

Cit-P Antigen Recognition Domain

Transmembrane Domain

Signaling Domains

Research and Development Programs

We are advancing our science and applying our approach through the following programs.

Our Treg programs are designed to target large autoimmune indications.

By leveraging the unique ability of Tregs to restore immune tolerance, we aim to make a significant impact across high-burden indications.

SBT-77-7101

A novel regulatory T cell-based therapy in development for the treatment of rheumatoid arthritis and hidradenitis suppurativa.

An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.

Learn More About our 7101 Clinical Trial

Regeneron-Partnered Programs

Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.

In partnership with:

To learn more about our partnership with Regeneron, read our Press Release.

Our therapies are designed to address both sides of the immune imbalance.

In addition to restoring regulation through Treg cells, we also target the overactive effector T cells (Teffs) that drive inflammation and tissue destruction. One of our therapies is specifically engineered to deplete and deactivate highly activated Teffs at the site of disease, helping to restore immune harmony and prevent further damage.

SBT-11-5301

An effector T Cell-modulating biologic for autoimmune diseases.

SBT-11-5301 is a biologic designed to eliminate highly activated effector T cells (T_eff) that are dominant in autoimmune and inflammatory disease.

We have completed a Phase 1 healthy volunteer study of SBT-11-5301 and plan to evaluate the product in combination with one of Treg programs in future clinical trials.

Our Platform

Our products target proteins that drive autoimmune and inflammatory responses in – multiple autoimmune diseases.

Learn More

Using our proprietary manufacturing process, we isolate, expand, and enhance Tregs from a patient’s own immune system to treat autoimmune and inflammatory diseases.

Manufacturing